| Literature DB >> 34063635 |
Datu Agasi Mohd Kamal1,2, Norizam Salamt1, Siti Sarah Mohamad Zaid3, Mohd Helmy Mokhtar1.
Abstract
Tea is one of the most widely consumed beverages worldwide after water, and green tea accounts for 20% of the total tea consumption. The health benefits of green tea are attributed to its natural antioxidants, namely, catechins, which are phenolic compounds with diverse beneficial effects on human health. The beneficial effects of green tea and its major bioactive component, (-)-epigallocatechin-3-gallate (EGCG), on health include high antioxidative, osteoprotective, neuroprotective, anti-cancer, anti-hyperlipidemia and anti-diabetic effects. However, the review of green tea's benefits on female reproductive disorders, including polycystic ovary syndrome (PCOS), endometriosis and dysmenorrhea, remains scarce. Thus, this review summarises current knowledge on the beneficial effects of green tea catechins on selected female reproductive disorders. Green tea or its derivative, EGCG, improves endometriosis mainly through anti-angiogenic, anti-fibrotic, anti-proliferative and proapoptotic mechanisms. Moreover, green tea enhances ovulation and reduces cyst formation in PCOS while improving generalised hyperalgesia, and reduces plasma corticosterone levels and uterine contractility in dysmenorrhea. However, information on clinical trials is inadequate for translating excellent findings on green tea benefits in animal endometriosis models. Thus, future clinical intervention studies are needed to provide clear evidence of the green tea benefits with regard to these diseases.Entities:
Keywords: catechin; dysmenorrhea; endometriosis; epigallocatechin-3-gallate; polycystic ovary syndrome
Year: 2021 PMID: 34063635 PMCID: PMC8124874 DOI: 10.3390/molecules26092675
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Different properties of green tea, oolong tea and black tea.
| Properties | |||
|---|---|---|---|
| Green Tea | Oolong Tea | Black Tea | |
| Consumption | 20% | <2% | 75% |
| Main consumer | Asian | Asian | European and North Americans |
| Preparation | Non-fermented | Semi-fermented | Fully fermented |
| Characteristics | Green colourRetain almost all original polyphenol contents | Combine freshness of green tea and the fragrance of black tea | Reddish black colour, mellow flavour, low bitterness and astringency |
| Chemical Profile | |||
| Caffeine (mg/g) | 34.86 ± 4.32 | 19.67 ± 2.95 | 28.54 ± 3.68 |
| Total catechins (mg/g) | 105.85 ± 35.69 | 86.91 ± 23.54 | 10.18 ± 6.68 |
| Epigallocatechin-3-gallate (EGCG) (mg/g) | 18.10–54.06 | 7.36–38.36 | 2.19–9.18 |
| Epigallocatechin (EGC) (mg/g) | 13.44–36.53 | 3.57–30.61 | 0.31–3.23 |
| Epicatechin (EC) (mg/g) | 4.90–7.27 | 1.75–7.00 | 0.71–2.19 |
| Epicatechin-3-gallate (ECG) (mg/g) | 5.34–17.10 | 3.07–5.09 | 2.65–8.92 |
| Total Theaflavins (mg/g) | 0.88–5.56 | 0.66–3.63 | 10.70–17.28 |
| L-theanine (mg/g) | 2.16–4.03 | 0.41–1.29 | 0.88–1.37 |
Figure 1Beneficial effects of green tea catechins on endometriosis, polycystic ovary syndrome (PCOS) and dysmenorrhea.
In vivo studies found related to the effects of green tea catechins on endometriosis.
| Treatment | Treatment Duration | Type of Study | Findings | Conclusion | References |
|---|---|---|---|---|---|
| 1. 50 mg/kg/day green tea Epigallocatechin-3-gallate (EGCG) | Daily | Hetero-transplants of eutopic endometrium from patients with stage III endometriosis into severely compromised immunodeficient (SCID) mice | In the EGCG treated group: | EGCG suppresses the development of experimental endometriosis through the anti-angiogenic mechanism. | [ |
| 1. 50 mg/kg/day EGCG | Daily | 1. Hetero-transplants of eutopic endometrium from patients with stage III endometriosis into severely compromised immunodeficient (SCID) ovariectomised mice | EGCG inhibited microvessel development in endometriotic implants. | EGCG inhibited angiogenesis and suppressed VEGFC/VEGFR2 expression and signalling pathway. | [ |
| 1. EGCG 50 mg/kg/day | Daily for 14 days | 1. Hetero-transplants of endometrium from patients with endometriosis into severely compromised immunodeficient (SCID) ovariectomised mice | Significant lower scores for both Sirius red and Masson trichrome staining in EGCG treated mice. | EGCG inhibits fibrosis in endometriosis | [ |
| 1. 20 mg/kg EGCG | Daily for 4 weeks | Transplantation of mouse uterine horns to the mouse bowel mesentery to induce endometriotic-like lesions in a BALB/c mouse model | EGCG and resveratrol significantly reduced the number and volume of endometriotic lesions. | EGCG treatment inhibits the development and reduces the size of endometriotic lesions by reducing cell proliferation and increasing apoptotic activity. | [ |
| 1. 50 mg/kg pro-EGCG (EGCG octaacetate). | Daily for 4 weeks | Transplantation of endometrial tissues from transgenic luciferase expressing (CMV-Luc) mice into non-luminescent NOD-SCID mice | EGCG and pro-EGCG significantly decreased endometrial implant growth from the 2nd week to the 4th week. | Pro-EGCG significantly inhibited the development, growth, and angiogenesis of experimental endometriosis in mice with greater efficacy, better bioavailability, and greater anti-oxidation and anti-angiogenesis | [ |
| 1. 65 mg/kg EGCG | Daily for 14 days | Transplantation of endometrium and ovarian follicles to Syrian golden hamster dorsal skinfold chamber model | EGCG group had significant reduction in the number and density of microvessels development within the endometriotic lesions but not in ovarian follicles. | EGCG prevents the establishment of new endometriotic lesions. | [ |
| 1. 8.333 mg/mL EGCG | Once in 2 days for 16 days | Hetero-transplants of human endometrium into BALB/c female nude mice | Ectopic lesion growth: | EGCG may inhibit the growth of the endometrial lesion, affect the expression of E-cadherin and reduce the status of DNA methylation of the E-cadherin promoter region. | [ |
In vitro studies found related to the effects of green tea on endometriosis.
| Treatment | Treatment Duration | Type of Cell | Findings | Conclusion | References |
|---|---|---|---|---|---|
| 1. EGCG (10–50 µM) | 4 h | Human microvascular endothelial cells | EGCG suppressed VEGF-C expression and reduced VEGFR-2 and ERK activation. | EGCG inhibited angiogenesis and suppressed VEGFC/VEGFR2 expression and signalling pathway | [ |
| 1. EGCG 50 or 100 µM | 8–24 h | Endometrial and endometriotic stromal cells | EGCG significantly inhibited cell proliferation, migration and invasion. | EGCG inhibits fibrosis in endometriosis | [ |
| 1. EGCG (0, 20, 40, 80 and 100 µM) | 24 h | Primary cultures of human endometrial epithelial cells from patient with endometriosis | Reduction in cell proliferation and increase in apoptosis. | EGCG treatment inhibits the development of endometriotic lesions by reducing cell proliferation and increasing apoptotic activity. | [ |
| 1. 40 µM EGCG. | Isolated hamster endometrial stromal and glandular cells | EGCG suppressed E2-stimulated activation, proliferation and VEGF expression of endometrial cells. | EGCG prevents the establishment of new endometriotic lesions. | [ |
Figure 2Mechanism related to the beneficial effects of green tea catechins on endometriosis.
Studies found related to the effects of green tea catechins on PCOS.
| Treatment | Treatment Duration | Type of Study | Findings | Conclusion | References |
|---|---|---|---|---|---|
| 1. Green tea tablet with unspecified dose | Daily for 12 weeks | Randomized | Significant reduction in weight and fasting insulin and testosterone levels in the green tea treated group compared with the placebo group. | The consumption of green tea by overweight and obese women suffering from PCOS leads to weight loss, a decrease in fasting insulin, and a decrease in the level of free testosterone. | [ |
| 1. Tablets equivalent to 500 mg green tea (C. Sinensis L.) leaf powder | Daily for 45 days | Randomized | No change found in height, | Consumption of green tea tablets did not cause any effect on inflammation biomarkers in PCOS | [ |
| 1. Capsules containing 2% freeze-dried tea powder, equivalent to 540 mg epigallocatechin-3-gallate. | Daily for three months | Randomized placebo-controlled trial on obese PCOS | No significant difference in body weight, BMI and body fat content between treatment and placebo group. | Green tea supplementation did not significantly reduce body weight in obese women with | [ |
| 1. 50,100 and 200 mg/kg body weight of hydro-alcoholic green tea extract | Intraperitoneally daily for 10 days | Adult female Wistar rats treated with estradiol valerate to induce PCOS | Significant decrease in the levels of LH and testosterone but no significant change in FSH level. | Green tea consumption causes modulating gonadotropin levels, reducing insulin resistance, | [ |
Studies found related to the effects of green tea catechins on dysmenorrhea.
| Treatment | Treatment Duration | Type of Study | Findings | Conclusion | References |
|---|---|---|---|---|---|
| Green tea intake | Not specified | A cross-sectional study involving reproductive age women in Shanghai, China. | Consumption of green tea was associated with | Consumptions of green tea | [ |
| 1. 5 mg/kg EGCG | Daily for 3 weeks | Mice treated with 1 mg/kg tamoxifen to induce adenomyosis | EGCG treatment: Suppressed myometrial infiltration. | EGCG shows a benefit in treating adenomyosis in an animal study. | [ |